CN105727247A - 一种修复关节慢性劳损的亲体性饮品 - Google Patents
一种修复关节慢性劳损的亲体性饮品 Download PDFInfo
- Publication number
- CN105727247A CN105727247A CN201610074623.2A CN201610074623A CN105727247A CN 105727247 A CN105727247 A CN 105727247A CN 201610074623 A CN201610074623 A CN 201610074623A CN 105727247 A CN105727247 A CN 105727247A
- Authority
- CN
- China
- Prior art keywords
- potassium
- calcium
- sodium
- parent
- beverage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 8
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 20
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 20
- 229910001414 potassium ion Inorganic materials 0.000 claims abstract description 14
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims abstract description 4
- 235000013361 beverage Nutrition 0.000 claims description 17
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- 239000001509 sodium citrate Substances 0.000 claims description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 8
- 239000001508 potassium citrate Substances 0.000 claims description 7
- 229960002635 potassium citrate Drugs 0.000 claims description 7
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 7
- 235000011082 potassium citrates Nutrition 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229960005069 calcium Drugs 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 239000004227 calcium gluconate Substances 0.000 claims description 5
- 235000013927 calcium gluconate Nutrition 0.000 claims description 5
- 229960004494 calcium gluconate Drugs 0.000 claims description 5
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 235000011147 magnesium chloride Nutrition 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- GYUKEMYHXWICKF-UHFFFAOYSA-N [Ca].NC(CC(O)=O)C(O)=O Chemical compound [Ca].NC(CC(O)=O)C(O)=O GYUKEMYHXWICKF-UHFFFAOYSA-N 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 235000009973 maize Nutrition 0.000 claims description 3
- 229960003975 potassium Drugs 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 229960002816 potassium chloride Drugs 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 229960002713 calcium chloride Drugs 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 2
- 239000000174 gluconic acid Substances 0.000 claims 2
- 235000012208 gluconic acid Nutrition 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 235000001465 calcium Nutrition 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 235000007686 potassium Nutrition 0.000 claims 1
- 229940094025 potassium bicarbonate Drugs 0.000 claims 1
- 229940093956 potassium carbonate Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 24
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 abstract description 13
- 229920001661 Chitosan Polymers 0.000 abstract description 12
- 239000004386 Erythritol Substances 0.000 abstract description 11
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 abstract description 11
- 239000004376 Sucralose Substances 0.000 abstract description 11
- 229940009714 erythritol Drugs 0.000 abstract description 11
- 235000019414 erythritol Nutrition 0.000 abstract description 11
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 abstract description 11
- 229940013618 stevioside Drugs 0.000 abstract description 11
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 abstract description 11
- 235000019202 steviosides Nutrition 0.000 abstract description 11
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 abstract description 11
- 235000019408 sucralose Nutrition 0.000 abstract description 11
- 108010053775 Nisin Proteins 0.000 abstract description 10
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 abstract description 10
- 239000004309 nisin Substances 0.000 abstract description 10
- 235000010297 nisin Nutrition 0.000 abstract description 10
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 abstract description 9
- 230000007774 longterm Effects 0.000 abstract description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 abstract 1
- 229940010747 sodium hyaluronate Drugs 0.000 abstract 1
- 230000003204 osmotic effect Effects 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 239000001755 magnesium gluconate Substances 0.000 description 8
- 235000015778 magnesium gluconate Nutrition 0.000 description 8
- 229960003035 magnesium gluconate Drugs 0.000 description 8
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000281 joint capsule Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 3
- 239000004224 potassium gluconate Substances 0.000 description 3
- 235000013926 potassium gluconate Nutrition 0.000 description 3
- 229960003189 potassium gluconate Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000001621 Mucoproteins Human genes 0.000 description 2
- 108010093825 Mucoproteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- -1 Stevioside Glycosides Chemical class 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000005123 simple squamous epithelium Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种修复关节慢性劳损的亲体性饮品,由以下重量百分比的组分组成:透明质酸钠:0.050.5%;壳聚(寡)糖:0.050.5%;低聚肽:0.11.0%;钙离子:0.050.1%;镁离子:0.0250.05%;钾离子:0.020.04%;钠离子:0.010.02%;赤藓糖醇:2.04.0%;三氯蔗糖:0.0050.01%;甜菊糖苷:0.0010.01%;乳酸链球菌素:0.010.02%;食用香精:0.030.1%;水:余量。长期饮用本发明的亲体性饮品,能够有效修复关节慢性劳损。
Description
技术领域
本发明涉及一种修复关节慢性劳损的亲体性饮品。
背景技术
骨关节是由相邻的骨之间借结缔组织构成的囊连接。骨关节主要由关节面、关节囊、关节腔组成,关节腔内有滑液。
关节面是各骨相互接触处的光滑面,是一层关节软骨,它属于结缔组织材料。关节软骨是透明软骨,无软骨膜,无血管、淋巴管及神经。关节软骨由细胞、基质及纤维构成。基质呈凝胶状,由黏蛋白和水构成,黏蛋白主干是透明质酸,其上结合了许多蛋白质链,蛋白链上又结合了许多硫酸软骨素及硫酸角质素,基质中水分约占基质75%;纤维主要是胶原原纤维(占软骨间质干重的50-70%)。
关节囊由外表纤维层与内面滑膜层构成。纤维层属于致密结缔组织材料,内有丰富血管、淋巴管与神经;滑膜层以薄层疏松结缔组织材料为基础,内面衬以单层扁平上皮组织材料。
关节腔是指由关节面与关节囊形成的腔结构,腔内主要物质就是关节囊分泌的关节滑液。关节滑液与血浆相似,基本成分为滑膜血管内血浆渗出,同时还包括滑膜被覆上皮细胞的分泌物,如:透明质酸、胶原蛋白及蛋白多糖,使滑液具有粘质性。其为无色或淡黄色粘稠液体,微碱性,pH值7.30-7.43(血浆pH值7.35-7.45),水分约为90%,固含量约4%,比重1.009-1.012;细胞个数(主要白细胞)≤0.2x109,蛋白总量18g/L,透明质酸含量1.91-3.23mg/mL。关节滑液对关节软骨起到润滑、营养滋润、排出毒素的作用。
发明内容
本发明的目的是提供一种修复关节慢性劳损的亲体性饮品。
根据本发明的亲体性饮品,由以下重量百分比的组分组成:
本发明饮品的亲体性特征指标:pH值:7.5-8.5、渗透压:270-310mmol/L、钾离子/钠离子≥2∶1。
本发明中低聚肽为小麦低聚肽、玉米低聚肽、大豆低聚肽、胶原蛋白肽中的一种或几种;钙离子选取葡萄糖酸钙、柠檬酸钙、乳酸钙、氯化钙、甘氨酸钙、天门冬氨酸钙、β-羟基-β-甲基丁酸钙中的一种或几种,镁离子选取葡萄糖酸镁、氯化镁、硫酸镁中的一种或几种,钾离子选取葡萄糖酸钾、氯化钾、柠檬酸钾、碳酸钾、碳酸氢钾、磷酸二氢钾中的一种或几种,钠离子选取柠檬酸钠、碳酸钠、碳酸氢钠、磷酸二氢钠中的一种或几种。
本发明以透明质酸钠、壳聚(寡)糖、低聚肽、钙离子、镁离子为核心,兼具与体液亲体性的特点。
透明质酸钠是关节滑液及关节软骨主链的核心物质;壳聚糖或壳寡糖具有比氨基葡萄糖更易于吸收的特点;低聚肽是可以快速转化为蛋白质及各种生物酶的物质;钙离子构成骨骼的成分,同时可以维持肌肉与神经的兴奋;镁离子构成骨骼的成分,维持神经与肌肉的正常功能,同时与许多生物酶的活性相关联。骨关节修复过程,不单纯是关节滑液及软骨及骨组织成分的补充,同时与神经调节及体液调节密切相关。
亲体性主要体现三个方面:一是本发明饮品的pH值为弱碱性(7.5-8.5),与血液及关节滑液的弱碱性相一致,二是本发明饮品与体液内环境的渗透压相一致,为270-310mmol/L,三是本发明饮品与人体合理钾钠比(≥2∶1)相一致,细胞内液高钾梯度(关联静息电位)与细胞外液高钠梯度(关联动作电位)是维持人体细胞生物电的基础,合理钾钠比的补充有利于维持细胞内外液的钾钠梯度。本发明的亲体性利于体液补充更趋完善,同时避免吸收及传递过程的负面干扰作用。
长期饮用本发明的亲体性饮品,能够有效修复关节慢性劳损。
具体实施方式:
按照下述实施例中列出的组分和重量百分比,配制根据本发明的饮品,配制条件是:在常压状态下,先按比例加入纯净水并加热至60度,再在搅拌状态下依次按比例加入其它组份,约搅拌一小时至溶解均匀,即为成品。
实施例1
透明质酸钠:0.05%;壳聚糖:0.05%;小麦低聚肽:0.17%;葡萄糖酸钙:0.56%;葡萄糖酸镁:0.44%;柠檬酸钾(一水):0.056%;柠檬酸钠(二水):0.044%;赤藓糖醇:2.0%;三氯蔗糖:0.01%;甜菊糖苷:0.01%;乳酸链球菌素:0.01%;食用香精:0.1%;纯净水:余量。
亲体性指标值:pH值=7.67、渗透压=275mmol/L、钾离子/钠离子=2.0∶1。
实施例2
透明质酸钠:0.06%;壳寡糖:0.06%;玉米低聚肽:0.15%;葡萄糖酸钙:0.56%;葡萄糖酸镁:0.44%;柠檬酸钾(一水):0.056%;柠檬酸钠(二水):0.044%;赤藓糖醇:2.5%;三氯蔗糖:0.01%;甜菊糖苷:0.01%;乳酸链球菌素:0.01%;食用香精:0.1%;纯净水:余量。
亲体性指标值:pH值=7.85、渗透压=296mmol/L、钾离子/钠离子=2.0∶1。
实施例3
透明质酸钠:0.07%;壳寡糖:0.05%;大豆低聚肽:0.15%;葡萄糖酸钙:0.56%;葡萄糖酸镁:0.44%;柠檬酸钾(一水):0.056%;柠檬酸钠(二水):0.044%;赤藓糖醇:2.6%;三氯蔗糖:0.01%;甜菊糖苷:0.01%;乳酸链球菌素:0.01%;食用香精:0.1%;纯净水:余量。
亲体性指标值:pH值=7.81、渗透压=290mmol/L、钾离子/钠离子=2.0∶1。
实施例4
透明质酸钠:0.5%;壳聚糖:0.35%;小麦低聚肽:0.10%;柠檬酸钙:0.36%;氯化镁:0.15%;氯化钾:0.058%;碳酸钠:0.028%;赤藓糖醇:3.5%;三氯蔗糖:0.005%;甜菊糖苷:0.005%;乳酸链球菌素:0.02%;食用香精:0.03%;纯净水:余量。
亲体性指标值:pH值=8.15、渗透压=310mmol/L、钾离子/钠离子=2.5∶1。
实施例5
透明质酸钠:0.20%;壳聚糖:0.5%;胶原蛋白肽:0.17%;乳酸钙:0.50%;葡萄糖酸镁:0.67%;碳酸氢钾:0.077%;碳酸氢钠:0.037%;赤藓糖醇:3.3%;三氯蔗糖:0.008%;甜菊糖苷:0.008%;乳酸链球菌素:0.005%;食用香精:0.08%;纯净水:余量。
亲体性指标值:pH值=8.0、渗透压=300mmol/L、钾离子/钠离子=3.0∶1。
实施例6
透明质酸钠:0.30%;壳聚糖:0.30%;小麦低聚肽:0.5%;氯化钙:0.22%;氯化镁:0.12%;葡萄糖酸钾:0.11%;碳酸氢钠:0.037%;赤藓糖醇:2.5%;三氯蔗糖:0.01%;甜菊糖苷:0.01%;乳酸链球菌素:0.01%;食用香精:0.05%;纯净水:余量。
亲体性指标值:pH值=8.11、渗透压:290mmol/L、钾离子/钠离子=2.0∶1。
实施例7
透明质酸钠:0.40%;壳聚糖:0.20%;小麦低聚肽:0.35%;天门冬氨酸钙:0.38%;葡萄糖酸镁:0.43%;磷酸二氢钾:0.11%;柠檬酸钠:0.043%;赤藓糖醇:3.0%;三氯蔗糖:0.01%;甜菊糖苷:0.01%;乳酸链球菌素:0.01%;食用香精:0.1%;纯净水:余量。
亲体性指标值:pH值=8.12、渗透压=298mmol/L、钾离子/钠离子=3.0∶1。
实施例8
透明质酸钠:0.32%;壳聚糖:0.05%;小麦低聚肽:0.25%;β-羟基-β-甲基丁酸钙:0.31%;葡萄糖酸镁:0.44%;柠檬酸钾(一水):0.056%;柠檬酸钠(二水):0.043%;赤藓糖醇:3%;三氯蔗糖:0.01%;甜菊糖苷:0.01%;乳酸链球菌素:0.01%;食用香精:0.1%;纯净水:余量。
亲体性指标值:pH值=8.01、渗透压=306mmol/L、钾离子/钠离子=2.0∶1。
实施例9
透明质酸钠:0.35%;壳聚糖:0.15%;小麦低聚肽:0.45%;甘氨酸钙:0.24%;硫酸镁:0.13%;葡萄糖酸钾:0.12%;柠檬酸钠(二水):0.044%;赤藓糖醇:3.0%;三氯蔗糖:0.01%;甜菊糖苷:0.01%;乳酸链球菌素:0.01%;食用香精:0.1%;纯净水:余量。
亲体性指标值:pH值=7.95、渗透压=298mmol/L、钾离子/钠离子=2.0∶1。
实施例10
透明质酸钠:0.05%;壳聚糖:0.05%;小麦低聚肽:0.25%;β-羟基-β-甲基丁酸钙:0.31%;葡萄糖酸镁:0.44%;柠檬酸钾(一水):0.056%;柠檬酸钠(二水):0.044%;赤藓糖醇:2.5%;三氯蔗糖:0.01%;甜菊糖苷:0.01%;乳酸链球菌素:0.01%;食用香精:0.1%;纯净水:余量。
亲体性指标值:pH值=8.23、渗透压276mmol/L、钾离子/钠离子=2.0∶1。
●使用效果
实验说明:
选取三个年龄组进行三个月实验,每个年龄组各十人,每人睡前一小时饮用本发明饮品一瓶(350毫升)。三个年龄组分别为:I组十人,25岁-40岁;II组十人,40岁-60岁;III组十人:60岁-80岁。
实验记录:
注:A:无效;B:微效;C:显效。
实验结论:
实验三个月,I组、II组、III组显效率分别为80%、70%、60%,总的显效率为70%,总有效率为80%。
Claims (6)
1.一种修复关节慢性劳损的亲体性饮品,由以下重量百分比的组分组成:
2.如权利要求1所述的亲体性饮品,其中低聚肽为小麦低聚肽、玉米低聚肽、大豆低聚肽、胶原蛋白肽中的一种或几种。
3.如权利要求1所述的亲体性饮品,其中钙离子为葡萄糖酸钙、柠檬酸钙、乳酸钙、氯化钙、甘氨酸钙、天门冬氨酸钙、β-羟基-β-甲基丁酸钙中的一种或几种。
4.如权利要求1所述的亲体性饮品,其中镁离子包含葡萄糖酸镁、氯化镁、硫酸镁中的一种或几种。
5.如权利要求1所述的亲体性饮品,其中钾离子包含葡萄糖酸钾、氯化钾、柠檬酸钾、碳酸钾、碳酸氢钾、磷酸二氢钾中的一种或几种。
6.如权利要求1所述的亲体性饮品,其中钠离子包含柠檬酸钠、碳酸钠、碳酸氢钠、磷酸二氢钠中的一种或几种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610074623.2A CN105727247A (zh) | 2016-02-03 | 2016-02-03 | 一种修复关节慢性劳损的亲体性饮品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610074623.2A CN105727247A (zh) | 2016-02-03 | 2016-02-03 | 一种修复关节慢性劳损的亲体性饮品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105727247A true CN105727247A (zh) | 2016-07-06 |
Family
ID=56245741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610074623.2A Pending CN105727247A (zh) | 2016-02-03 | 2016-02-03 | 一种修复关节慢性劳损的亲体性饮品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105727247A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108056353A (zh) * | 2017-12-07 | 2018-05-22 | 青岛明药堂医疗股份有限公司 | 一种含甲壳素衍生物的等渗固体饮品及其制备、使用方法 |
CN108783138A (zh) * | 2018-07-05 | 2018-11-13 | 青岛海芬生态科技有限公司 | 一种女性养颜保健饮品及其制备方法 |
CN112998168A (zh) * | 2021-04-23 | 2021-06-22 | 绿优品(福建)健康科技研发中心有限公司 | 一种透明质酸复合多肽饮品及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1439313A (zh) * | 2003-04-02 | 2003-09-03 | 李安虎 | 一种关节保健饮品或食品及其制备方法 |
CN101085357A (zh) * | 2007-06-29 | 2007-12-12 | 中国人民解放军南京军区南京总医院 | 一种用于关节腔内注射治疗软骨缺损的非病毒纳米核酸转运复合物及其制备方法 |
CN101756336A (zh) * | 2009-12-15 | 2010-06-30 | 刘天银 | 一种保健饮料及其制备方法 |
CN102960697A (zh) * | 2012-11-30 | 2013-03-13 | 苏州工业园区尚融科技有限公司 | 膳食纤维饮品适用的复合甜味剂及其制备方法 |
CN103238839A (zh) * | 2013-05-15 | 2013-08-14 | 百岳特生物科技(上海)有限公司 | 用于保养关节的含胶原蛋白的食品组成物 |
-
2016
- 2016-02-03 CN CN201610074623.2A patent/CN105727247A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1439313A (zh) * | 2003-04-02 | 2003-09-03 | 李安虎 | 一种关节保健饮品或食品及其制备方法 |
CN101085357A (zh) * | 2007-06-29 | 2007-12-12 | 中国人民解放军南京军区南京总医院 | 一种用于关节腔内注射治疗软骨缺损的非病毒纳米核酸转运复合物及其制备方法 |
CN101756336A (zh) * | 2009-12-15 | 2010-06-30 | 刘天银 | 一种保健饮料及其制备方法 |
CN102960697A (zh) * | 2012-11-30 | 2013-03-13 | 苏州工业园区尚融科技有限公司 | 膳食纤维饮品适用的复合甜味剂及其制备方法 |
CN103238839A (zh) * | 2013-05-15 | 2013-08-14 | 百岳特生物科技(上海)有限公司 | 用于保养关节的含胶原蛋白的食品组成物 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108056353A (zh) * | 2017-12-07 | 2018-05-22 | 青岛明药堂医疗股份有限公司 | 一种含甲壳素衍生物的等渗固体饮品及其制备、使用方法 |
CN108783138A (zh) * | 2018-07-05 | 2018-11-13 | 青岛海芬生态科技有限公司 | 一种女性养颜保健饮品及其制备方法 |
CN112998168A (zh) * | 2021-04-23 | 2021-06-22 | 绿优品(福建)健康科技研发中心有限公司 | 一种透明质酸复合多肽饮品及其制备方法 |
CN112998168B (zh) * | 2021-04-23 | 2023-09-15 | 绿优品(福建)健康科技研发中心有限公司 | 一种透明质酸复合多肽饮品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102077936B (zh) | 一种糖尿病患者专用的海洋特膳食品 | |
CN109170469A (zh) | 一种鱼胶原蛋白肽固体饮料及其制备方法 | |
CN102077945B (zh) | 一种人流、产后专用的海洋特膳食品 | |
CN109363006A (zh) | 一种胶原蛋白肽饮品 | |
CN105727247A (zh) | 一种修复关节慢性劳损的亲体性饮品 | |
CN107712691A (zh) | 一种花胶炖品及其制作方法 | |
CN102077939A (zh) | 一种肥胖人士专用的海洋特膳食品 | |
CN105918742A (zh) | 一种助眠排毒养颜饮品 | |
CN108157878A (zh) | 一种高纤钙强化胶原蛋白果冻及其制备方法 | |
CN102077944B (zh) | 一种前列腺患者专用的海洋特膳食品 | |
CN102077942A (zh) | 一种骨病患者专用的海洋特膳食品 | |
CN109329834A (zh) | 一种枸杞抗疲劳保健食品及其制备方法 | |
CN103656626B (zh) | 一种中老年治骨养骨复方络合钙制剂及其制备方法 | |
CN103919227A (zh) | 一种具有增强记忆力作用的玉米低聚肽饮料及其生产工艺 | |
CN108740863A (zh) | 一种益气补血的组合物及其制备方法和应用 | |
CN102987206A (zh) | 一种降糖组合物 | |
CN105029568A (zh) | 黑蒜饮料及其制备方法 | |
CN109430650A (zh) | 制备胶原蛋白、透明质酸饮料和滋补液的配方与生产工艺 | |
CN112841312A (zh) | 一种胶原蛋白奶茶固体饮料及其食用方法 | |
CN105211854B (zh) | 蜜炼参草丹 | |
CN102835708A (zh) | 一种含有多种矿物质的保健饮料 | |
CN1319536C (zh) | 美肤剂及保健美容食品 | |
CN107279445A (zh) | 一种纠正人体亚健康状态的口香糖配方和生产工艺 | |
CN1994397A (zh) | 海参紫丹胶囊 | |
CN105166308A (zh) | 一种姜味口香糖及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160706 |
|
RJ01 | Rejection of invention patent application after publication |